ARMP — Armata Pharmaceuticals Income Statement
0.000.00%
- $99.43m
- $193.60m
- $4.53m
Annual income statement for Armata Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.823 | 4.47 | 5.51 | 4.53 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 20.9 | 23.5 | 27.6 | 42.5 | 49.3 |
Operating Profit | -20.9 | -22.7 | -23.1 | -36.9 | -44.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.5 | -22.2 | -23.2 | -36.9 | -69 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.5 | -22.2 | -23.2 | -36.9 | -69 |
Net Income Before Extraordinary Items | |||||
Net Income | -19.5 | -22.2 | -23.2 | -36.9 | -69 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.5 | -22.2 | -23.2 | -36.9 | -69 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.12 | -1.22 | -0.991 | -1.08 | -1.81 |